Age-related macular degeneration (AMD) is a multi-factorial disorder responsible for legal blindness in the elderly population, with the advanced stage characterized by geographic atrophy or choroidal neovascularization. As therapeutic agents barely access the macular region, they are delivered via intravitreal injection. Despite the encouraging outcomes in healing and improved vision, the intravitreal technique is frequently accompanied by devastating complications, thus calling for usage of nanotechnology to boost artificial retention of medications and avoidance of repeated injections. This chapter summarizes pathophysiology of AMD and nanotechnology-enabled applications used to deal with this disorder.